



Overview of the Advance HIV Disease Monitoring and Evaluation in Nigeria

Bodunde Onifade (Dr.)

National Lead, HIV Data management, National HIV/AIDS/STIs Control Programme, Abuja. FCT. Nigeria.

29 July 2020




HIV LEARNING NETWORK
The CQUIN Project for Differentiated Service Delivery

Background

WHO definition of AHD

- **Adults and adolescents, and children older than five years, advanced HIV disease is defined as CD4+ lymphocyte count <200cells/mm³ or WHO stage 3 or 4 event**
- **All children younger than five years old with HIV are considered as having advanced HIV disease**



In Nigeria

- Recommendations on the diagnosis and management of AHD were not clearly articulated in the National Treatment Guidelines
- A package of care for AHD was developed for the National HIV program in Nigeria in 2019
- Rollout of the package of care was designed to commence at 28 ART sites followed by a national scale-up
- Existing national M&E tools were not designed to monitor some AHD specific indicators
- NASCP constituted a team of stakeholders to review tools to capture the developed AHD package of care

Components of M&E for AHD



INDICATORS

- A total of 15 indicators
- 6 indicators as minimal requirements for routine reporting
- Indicator reference sheet developed



TOOLS

- Adult Initial Clinical Evaluation form.
- ART Care Card
- Enrolment Register
- ART Register
- Combined Pharmacy Order Form
- Pharmacy Daily Worksheet
- Client Tracking Register
- Client Tracking & Termination Form
- Lab Order & Result Form
- ART Monthly Summary Form

AHD Indicators

AHD Diagnosis

1

% of newly enrolled PLHIV assessed for WHO clinical staging at enrolment into care (before ART initiation)

2

% of newly enrolled PLHIV with CD4+ cell count result received at enrolment into care (before ART initiation). (baseline CD4 cell count)

3

% of new PLHIV presenting with AHD at enrolment into care (before ART initiation). (one count for each patient)

4

% of PLHIV presenting with AHD without OIs commenced on ART within 7 days of enrollment. (OI's- Cryptococcal infections and Tuberculosis)

OI Diagnosis and Management

5

% of newly enrolled PLHIV in care presenting with AHD who were clinically screened for TB

6

% of newly enrolled PLHIV with AHD and presumptive TB diagnosed with active TB disease

7

% of newly enrolled PLHIV presenting with AHD screened for CrAg before ART initiation

8

% of newly enrolled PLHIV presenting with AHD who have CrAg+ results before ART initiation

9

% of newly enrolled PLHIV presenting with AHD diagnosed with Cryptococcal meningitis before ART initiation

10

% of newly enrolled PLHIV presenting with AHD diagnosed with Cryptococcal meningitis who were started on Tx before ART initiation.

11

% of enrolled PLHIV presenting with AHD who completed the treatment for Cryptococcal meningitis.

Monitoring / Follow up

12

% of newly enrolled PLHIV presenting with AHD provided with Intensive adherence support (weekly phone calls) for the first 4 weeks following enrollment

13

% of PLHIV presenting with AHD retained in treatment at 6, 12 and 24 months after ART initiation.

14


% of PLHIV presenting with AHD who have documented viral load test result during the reporting period.

15

% of PLHIV presenting with AHD who are virologically suppressed (<1,000 copies/ml) during the reporting period.

Disaggregation

Sex:



AGE GROUP

1, 1-4, 5-9, 10-14, 15-19, 20-24, 25-49, 50+

Facility Level Reporting Process



- Health Information Management staff
- Data clerk / PMM staff
- Clinician or ART/Triage Nurse
- Adherence counsellor/ Care and Support nurse
- Tracker



Tools should be filled as services are being provided by the service providers.



- In the medical records / patient management & monitoring/ monitoring & evaluation unit of the facility.
- keep safely in a filing cabinet



Next steps

- Training of M&E focal persons and other relevant health providers on appropriate documentation on updated M&E tools
- Roll-out of updated National M&E tools at selected health facilities
- Routine monitoring and supervision of data collection processes on National M&E tools
- Review of AHD indicators and data collection tools following the first phase of implementation at 28 ART sites
- Scale up updated M&E tools to additional ART sites after the implementation at the 28 selected facilities

